ACTU Stock Analysis: Buy, Sell, or Hold?
ACTU - Actuate Therapeutics, Inc. Common stock
$1.21
-0.02 (-1.63%)
▼
5d:
-20.39%
30d:
-39.8%
90d:
-35.98%
WAIT
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When ACTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ACTU is down 20.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ACTU is down 20.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACTU is currently trading at $1.21, which is considered oversold relative to its 30-day fair value range of $1.55 to $2.05.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $2.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.98 (+724.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACTU is in a strong downtrend. Immediate support is located at $1.16, while resistance sits at $2.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.98 (+724.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.55 -
$2.05
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 724.6% below Wall St target ($9.98)
- WARNING: Recommendation downgraded due to -20.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.55 -
$2.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$2.00
Current Trend
Strong Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.42
Wall Street Target
$9.98
(+724.6%)
Share & Embed Analysis
Last updated: July 13, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
